| Literature DB >> 34208045 |
Martina Rafanelli1, Giuseppe Dario Testa1, Giulia Rivasi1, Andrea Ungar1.
Abstract
The rate of syncope in the Emergency Department ranges between 0.9 and 1.7%. Syncope is mostly related to a underlying reflex or orthostatic mechanism. A bradycardic or a hypotensive phenotype, may be identified. The latter is the most common and could be constitutional or drug induced. Consequently, obtaining an accurate drug history is an important step of the initial assessment of syncope. As anti-hypertensive medication might be responsible for orthostatic hypotension, managing hypertension in patients with syncope requires finding an ideal balance between hypotensive and cardiovascular risks. The choice of anti-hypertensive molecule as well as the therapeutic regimen and dosage, influences the risk of syncope. Not only could anti-hypertensive drugs have a hypotensive effect but opioids and psychoactive medications may also be involved in the mechanism of syncope. Proper drug management could reduce syncope recurrences and their consequences.Entities:
Keywords: drugs; hypotensive phenotype; hypotensive susceptibility; orthostatic hypotension; pharmacological therapy; syncope
Mesh:
Substances:
Year: 2021 PMID: 34208045 PMCID: PMC8231040 DOI: 10.3390/medicina57060603
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Causes of syncope, adapted from Moya A. et al. [1].
|
|
| Vasovagal (VVS) |
| Situational |
| Carotid sinus syncope |
|
|
| Drug-induced orthostatic hypotension |
| Volume depletion |
| Secondary autonomic failure (diabetes, amyloidosis, spinal cord injuries, auto-immune autonomic neuropathy, paraneoplastic autonomic neuropathy, kidney failure) |
|
|
| Arrhythmia as primary cause: sinus node dysfunction atrioventricular conduction system disease implanted device malfunction supraventricular ventricular |
| Structural disease: |
|
|
| Pulmonary embolus, acute aortic dissection, pulmonary hypertension |
BP targets in patients with hypertension and treatment-related syncope, adapted from Rivasi et al. [31].
| Age < 70 | Age > 70 or Frailty | Disability | |
|---|---|---|---|
| Low syncope risk and | 120–130 mmHg | 130–140 mmHg | <160 mmHg |
| High syncope risk and | 130–140 mmHg |
Vaso-active drugs, adapted from Gibbons C.H. et al., 2017 [32].
| Classes of Drugs | Drugs |
|---|---|
| Dopaminergic agents | levodopa, dopamine agonists |
| Antidepressant | amytriptiline, nortryptiline, imipramine, desipramine |
| Anticholinergics | atropine, glycopyrrolate, hyoscyamine |
|
| |
| Diuretics | furosemide, torsemide, acetazolamide, spironolactone, hydrochlorothiazide |
| Nitrates | nitroprusside, isosorbide dinitrate, nitroglycerin |
| Phosphodiesterase E5 inhibitors | sildenafil, vardenafil, tadalafil |
| Alpha-1 adrenergic antagonists | alfuzosin, doxazosin, tamsulosin |
| Dihydropyridine calcium channel blockers | amlodipine, nifedipine, nicardipin |
| Other direct vasodilators | hydralazine, medoxidil |
|
| |
| Beta-adrenergic blockers | metroprolol, propranolo, atenolol, bisoprolol, etc. |
| Non dihydropyridine calcium channel blockers | verapamil, diltiazem |
|
| |
| Centrally acting alpha-2 agonists | clonidine |
| False neurotransmitters | alpha-methyldopa |
|
| |
| ACE inhibitors | captopril, enalapril, perindopril |
| ARB | losartan, telmisartan, candesartan |
Figure 1Antihypertensive medications that may increase the risk of orthostatic hypotension.
Key points for the management of hypotensive medications in syncope.
| Key Points |
|---|
| 1. Considering the reduction or withdrawal of hypotensive medication. |
| 2. Considering changing molecules or therapy regimen (preferring bedtime administration, except for diuretics) when it is not possible to withdraw a hypotensive medication. |
| 3. Preferring selective beta-blockers instead of alpha- and beta-receptor blockers, when indicated. |
| 4. Preferring uro-selective alpha-lytics in patients with BPH-associated LUTS (e.g., silodosin), when indicated. |
| 5. Avoiding diuretics, unless specifically indicated as essential. |
| 6. Considering renal and hepatic impairment in order to avoid drug accumulation. |
BPH: benign prostatic hyperplasia; LUTS: low urinary tract symptoms.